---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-042870"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:52:16.759996+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar Biosciences to explore strategic alternatives; hires Oppenheimer as advisor

## Summary
- Board authorized exploration of M&A, partnerships, licensing or other transactions; no deal reached.
- Oppenheimer & Co. retained as exclusive financial advisor for the strategic evaluation process.
- CEO James Caruso cites need for a partner to develop lead asset iopofosine I-131 and pipeline.
- Alpha- and Auger-emitting radioconjugates CLR 225 and CLR 125 in solid tumors are additional opportunities.
- No timetable set; company will not update progress unless a definitive agreement is reached.

## SEC filing metadata
- accession: 0001104659-25-042870
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925042870/0001104659-25-042870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925042870/tm2513754d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-042870
- JSON: https://secwatch.observer/filing/0001104659-25-042870.json
- Plain text: https://secwatch.observer/filing/0001104659-25-042870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.